8-K current report · filed Jul 8, 2026

Moderna (MRNA) 8-K Current Report: July 8, 2026

Item 5.02Item 7.01Item EX-99.1MRNA overview

Short answer

Moderna (MRNA) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Michael McDonnell appointed director effective July 8, 2026, bringing 35+ years of financial and public-company leadership.

Moderna 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Michael McDonnell appointed director effective July 8, 2026, bringing 35+ years of financial and public-company leadership
  • Former Biogen CFO adds biotechnology-sector expertise and strengthens board financial oversight
  • McDonnell joins Audit Committee; David Rubenstein shifts to Nominating and Corporate Governance Committee
  • Class II term runs through 2029 annual meeting, supporting board continuity
  • Eligible for initial and pro-rata annual director equity grants under Moderna’s compensation policy

Item 7.01 · Regulation FD Disclosure

  • Moderna announced McDonnell’s appointment to its Board, signaling a change in governance and strategic oversight
  • Event is furnished under Regulation FD, making the board appointment broadly available to investors
  • Exhibit 99.1 contains the press release and likely biographical details relevant to assessing McDonnell’s experience

Item EX-99.1 · Exhibit EX-99.1

  • Michael McDonnell appointed director effective July 8, 2026, adding more than 35 years of financial leadership
  • Audit Committee assignment strengthens board oversight during Moderna’s pipeline advancement and commercialization phase
  • Former Biogen CFO brings more than 24 years as a public-company CFO and biotechnology-sector expertise
  • Appointment supports capital allocation and operational planning ahead of multiple potential product launches
  • Forward-looking launch and strategy expectations remain subject to development, regulatory, and commercial risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Moderna 8-K filings

Get the next MRNA 8-K as it lands

Follow MRNA for push alerts, or ask the research agent what this filing means.